Skip to main content

Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient with Metastatic Gastric Adenocarcinoma

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5. https://doi.org/10.1126/science.aar4060.

    CAS  Article  PubMed  Google Scholar 

  2. Haikal A, Borba E, Khaja T, Doolittle G, Schmidt P. Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: a case report and literature review. Avicenna J Med. 2018;8:34–6. https://doi.org/10.4103/ajm.AJM_127_17.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–91. https://doi.org/10.1093/annonc/mdv383.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. Calabrese L, Velcheti V. Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases. Ann Rheum Dis. 2017;76:1–3. https://doi.org/10.1136/annrheumdis-2016-209782.

    CAS  Article  PubMed  Google Scholar 

  5. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of disease activity score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007;66:407–9.

    CAS  Article  Google Scholar 

  6. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26:1346–53.

    CAS  Article  Google Scholar 

  7. Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grunwald V, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18. https://doi.org/10.1016/j.ctrv.2016.02.003.

    CAS  Article  PubMed  Google Scholar 

  8. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. https://doi.org/10.1056/NEJMoa1504030.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30. https://doi.org/10.1056/NEJMoa1412082.

    CAS  Article  PubMed  Google Scholar 

  10. Kwok TSH, Bell MJ. Immune checkpoint inhibitor-induced rheumatoid arthritis: insights into an increasingly common aetiology of polyarthritis. BMJ Case Rep. 2019;12:e227995. https://doi.org/10.1136/bcr-2018-227995.

    Article  PubMed  Google Scholar 

  11. Syrigos K, Tsagouli S, Grapsa D. Nivolumab-induced recurrence of rheumatoid arthritis in a patient with advanced non-small cell lung cancer: a case report. Ann Intern Med. 2016;165:894–5. https://doi.org/10.7326/L16-0137.

    Article  PubMed  Google Scholar 

  12. Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76:43–50. https://doi.org/10.1136/annrheumdis-2016-209595.

    CAS  Article  PubMed  Google Scholar 

  13. Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, et al. Rheumatoid arthritis and polymyalgia rheumatic occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76:1747–50. https://doi.org/10.1136/annrheumdis-2017-211216.

    CAS  Article  PubMed  Google Scholar 

  14. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RRT, Sullivian MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26. https://doi.org/10.1002/art.39480.

    Article  PubMed  Google Scholar 

  15. Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, et al. Successful treatment of arthritis induced by check point inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76:2061–4. https://doi.org/10.1136/annrheumdis-2017-211560.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Anne M. O’Rourke, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Masataka Nishikawa.

Ethics declarations

Funding

No funding was received for this letter.

Conflict of interest

Masataka Nishikawa, Atsushi Goshima, Hajime Owaki, and Takeshi Fuji have no conflicts of interest to declare.

Ethics approval

This letter was approved by the Ethics Committee of Japan Community Healthcare Organization Osaka Hospital.

Informed consent

Informed consent was obtained from the patient before his death.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nishikawa, M., Goshima, A., Owaki, H. et al. Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient with Metastatic Gastric Adenocarcinoma. Clin Drug Investig 39, 1251–1254 (2019). https://doi.org/10.1007/s40261-019-00846-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-019-00846-w